Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

on behalf of the RADAR-CNS consortium

Research output: Contribution to journalArticlepeer-review

Abstract

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

Original languageEnglish
Pages (from-to)1647-1650
Number of pages4
JournalNeurological Sciences
Volume41
Issue number7
DOIs
Publication statusPublished - Jul 1 2020

Keywords

  • COVID-19
  • Multiple Sclerosis
  • Remote monitoring technologies

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study'. Together they form a unique fingerprint.

Cite this